28 Apr 2026
Deal: Trilegal advised Glenmark Life Sciences in relation to its initial public offering
10 Aug 2021
10 Aug 2021
Glenmark Life Sciences is a wholly owned subsidiary of Glenmark Pharmaceuticals, is a developer and manufacturer of select Active Pharmaceutical Ingredients.
Trilegal Advised Glenmark Life Sciences Limited in relation to its initial public offering (Offer). The Offer included a fresh issue of equity shares worth Rs. 1,160 crores and an offer for sale of 63 lakh equity shares by its parent company, Glenmark Pharmaceuticals Limited. We also advised Glenmark Pharmaceuticals Limited.
This is one of the first initial public offering by a pharmaceutical company engaged in the manufacturing of active pharmaceutical ingredients in the recent few years. This transaction saw the highest number of applications for subscription by any pharmaceutical company in India and the second highest number of applications in the history of the Indian capital markets with more than 40 lakh distinct applications.
Trilegal team was led by Bhakta Patnaik, Partner and was assisted by Albin George Thomas, Counsel; Arjun Rastogi, Senior Associate and other Associates.
S&R Associates were the Legal counsel to the BRLMs and Sidley Austin LLP were International Legal Counsel to the BRLMs.
For more information, please contact:
Sahil Wason
Tel: +91-8928008122
BD@Trilegal.com
Under the rules of the Bar Council of India, Trilegal is prohibited from soliciting work or advertising in any form or manner. By accessing this website, www.trilegal.com, you acknowledge that:
We prioritize your privacy. Before proceeding, we encourage you to read our privacy policy, which outlines the below, and terms of use to understand how we handle your data:
For more information, please read our terms of use and our privacy policy.
